Severine Denoyelle

1919 Route De Mende, Cedex 5
Montpellier, 34293, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Novel insights into the effects of JMV2894, a growth hormone secretagogue, in Duchenne muscular dystrophy: A preclinical study in the D2-mdx mouse model.

Novel insights into the effects of JMV2894, a growth hormone secretagogue, in Duchenne muscular dystrophy: A preclinical study in the D2-mdx mouse model.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 30, 2025

Growth hormone secretagogues modulate inflammation and fibrosis in mdx mouse model of Duchenne muscular dystrophy.

Growth hormone secretagogues modulate inflammation and fibrosis in mdx mouse model of Duchenne muscular dystrophy.

Journal: Frontiers in immunology

Published: December 09, 2022

Design and characterization of a triazole-based growth hormone secretagogue receptor modulator inhibiting the glucoregulatory and feeding actions of ghrelin.

Design and characterization of a triazole-based growth hormone secretagogue receptor modulator inhibiting the glucoregulatory and feeding actions of ghrelin.

Journal: Biochemical pharmacology

Published: April 11, 2022

GHSR controls food deprivation-induced activation of CRF neurons of the hypothalamic paraventricular nucleus in a LEAP2-dependent manner.

GHSR controls food deprivation-induced activation of CRF neurons of the hypothalamic paraventricular nucleus in a LEAP2-dependent manner.

Journal: Cellular and molecular life sciences : CMLS

Published: March 11, 2022

Circulating ghrelin crosses the blood-cerebrospinal fluid barrier via growth hormone secretagogue receptor dependent and independent mechanisms.

Circulating ghrelin crosses the blood-cerebrospinal fluid barrier via growth hormone secretagogue receptor dependent and independent mechanisms.

Journal: Molecular and cellular endocrinology

Published: June 09, 2021

LEAP2 Impairs the Capability of the Growth Hormone Secretagogue Receptor to Regulate the Dopamine 2 Receptor Signaling.

LEAP2 Impairs the Capability of the Growth Hormone Secretagogue Receptor to Regulate the Dopamine 2 Receptor Signaling.

Journal: Frontiers in pharmacology

Published: May 20, 2021

Allosteric modulation of ghrelin receptor signaling by lipids.

Allosteric modulation of ghrelin receptor signaling by lipids.

Journal: Nature communications

Published: October 21, 2020

Concerted conformational dynamics and water movements in the ghrelin G protein-coupled receptor.

Concerted conformational dynamics and water movements in the ghrelin G protein-coupled receptor.

Journal: eLife

Published: September 17, 2020

Development of Nonpeptidic Inverse Agonists of the Ghrelin Receptor (GHSR) Based on the 1,2,4-Triazole Scaffold.

Development of Nonpeptidic Inverse Agonists of the Ghrelin Receptor (GHSR) Based on the 1,2,4-Triazole Scaffold.

Journal: Journal of medicinal chemistry

Published: September 04, 2020

Development of a novel fluorescent ligand of growth hormone secretagogue receptor based on the N-Terminal Leap2 region.

Development of a novel fluorescent ligand of growth hormone secretagogue receptor based on the N-Terminal Leap2 region.

Journal: Molecular and cellular endocrinology

Published: July 11, 2019

Evaluation of amidoxime derivatives as prodrug candidates of potent bis-cationic antimalarials.

Evaluation of amidoxime derivatives as prodrug candidates of potent bis-cationic antimalarials.

Journal: Bioorganic & medicinal chemistry letters

Published: May 10, 2019

N-Terminal Liver-Expressed Antimicrobial Peptide 2 (LEAP2) Region Exhibits Inverse Agonist Activity toward the Ghrelin Receptor.

N-Terminal Liver-Expressed Antimicrobial Peptide 2 (LEAP2) Region Exhibits Inverse Agonist Activity toward the Ghrelin Receptor.

Journal: Journal of medicinal chemistry

Published: December 14, 2018

Showing 1-12 of 19

Last Updated: 09/26/2026